Literature DB >> 19397645

Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection.

Doris Hexsel1, Marcio S Rutowitsch, Lia Cândida M de Castro, Débora Zechmeister do Prado, Maryelle Moreira Lima.   

Abstract

BACKGROUND: It is recommended that attention be given to the shelf life of botulinum toxin type A (BT-A) after its reconstitution.
OBJECTIVE: To assess the efficacy and safety of 500 U of BT-A after reconstitution up to 15 days after injection.
MATERIAL AND METHODS: BT-A vials were diluted 15 days, 8 days, and 8 hours before injection. One hundred five volunteers were randomized to one of three treatment groups, according to dilution dates. They were evaluated at baseline and 28, 56, 84, and 112 days after treatment. At each visit, the investigator and the volunteer evaluated the motility of the treated area using a 4-point qualitative scale. Five independent specialists, who scored the motility of the treated area on the same scale, blind analyzed photographs taken at each visit. The reconstituted vials of BT-A were stored and analyzed before and after the study.
RESULTS: No significant difference was shown between the groups. No evidence of contamination was found in the BT-A vials.
CONCLUSION: The results confirm the possibility of injecting 500 U of BT-A up to 15 days after its reconstitution safely and without loss of efficacy.

Mesh:

Substances:

Year:  2009        PMID: 19397645     DOI: 10.1111/j.1524-4725.2009.01158.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

1.  Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model.

Authors:  Mark S Nestor; Glynis R Ablon
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

Review 2.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 3.  Onset and Duration of AbobotulinumtoxinA for Aesthetic Use in the Upper face: A Systematic Literature Review.

Authors:  Mark Nestor; Joel L Cohen; Marina Landau; Said Hilton; Andreas Nikolis; Syed Haq; Maurizio Viel; Bill Andriopoulos; Inna Prygova; Keith Foster; Alessio Redaelli; Philippe Picaut
Journal:  J Clin Aesthet Dermatol       Date:  2020-12-01

Review 4.  Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?

Authors:  Dirk Dressler; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2017-08-02       Impact factor: 3.575

5.  Botulinum toxin type A for the management of glabellar rhytids.

Authors:  Anne Marie Tremaine; Jerry L McCullough
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-07

Review 6.  Use of Botulinum Neurotoxin in Ophthalmology.

Authors:  Emel Başar; Ceyhun Arıcı
Journal:  Turk J Ophthalmol       Date:  2016-12-01

Review 7.  Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.

Authors:  Mark Nestor; Glynis Ablon; Andy Pickett
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.